Singapore markets close in 7 hours 25 minutes
  • Straits Times Index

    3,121.93
    +1.69 (+0.05%)
     
  • Nikkei

    26,414.37
    +260.56 (+1.00%)
     
  • Hang Seng

    21,830.35
    0.00 (0.00%)
     
  • FTSE 100

    7,232.65
    +64.00 (+0.89%)
     
  • BTC-USD

    20,274.98
    +1,107.79 (+5.78%)
     
  • CMC Crypto 200

    439.87
    +19.73 (+4.70%)
     
  • S&P 500

    3,825.33
    +39.95 (+1.06%)
     
  • Dow

    31,097.26
    +321.86 (+1.05%)
     
  • Nasdaq

    11,127.84
    +99.14 (+0.90%)
     
  • Gold

    1,810.10
    +8.60 (+0.48%)
     
  • Crude Oil

    111.11
    +2.68 (+2.47%)
     
  • 10-Yr Bond

    2.8890
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,442.65
    +5.13 (+0.36%)
     
  • Jakarta Composite Index

    6,639.17
    -155.16 (-2.28%)
     
  • PSE Index

    6,183.62
    0.00 (0.00%)
     

J&J strikes deal with Emergent BioSolutions on coronavirus vaccine manufacturing

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
FILE PHOTO: The company logo for Johnson & Johnson is displayed to celebrate the 75th anniversary of the company's listing at the NYSE in New York
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

(Reuters) - Johnson & Johnson said on Thursday it had struck a deal with Emergent BioSolutions Inc to use its manufacturing facilities to help in an effort to make more than 1 billion doses of a vaccine it is testing to stop the novel coronavirus.

The U.S. healthcare conglomerate said the deal was the first in a series of prospective global partnerships to accelerate manufacturing of its experimental COVID-19 vaccine candidate, even before it has a signal that it works.

J&J plans to start human testing by September, with an eye on having it ready under an emergency use authorization in early 2021, far quicker than the typical 18-month period that it takes for vaccines to be tested, approved and then manufactured.

Under the deal, valued at about $135 million, Emergent said it would provide drug substance manufacturing services and was reserving large-scale manufacturing capacity.

J&J and the U.S. government are investing $1 billion to create enough manufacturing capacity for the experimental vaccine candidate to stop the virus that has killed nearly 185,000 people around the globe.

(Reporting by Uday Sampath in Bengaluru; Editing by Subhranshu Sahu)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting